Alnylam Pharmaceuticals
ALNY
#638
Rank
S$38.94 B
Marketcap
$300.89
Share price
-6.98%
Change (1 day)
46.81%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.47. In 2022 the company made an earnings per share (EPS) of -$12.35 a decrease over its 2021 EPS that were of -$9.57.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-55.51%
2022-$12.3529.03%
2021-$9.57-3.36%
2020-$9.91-8.48%
2019-$10.827.67%
2018-$10.0539.74%
2017-$7.1912.94%
2016-$6.3738.84%
2015-$4.59-32.88%
2014-$6.83259.44%
2013-$1.90-31.25%
2012-$2.7752.94%
2011-$1.8130.77%
2010-$1.38-8.77%
2009-$1.5278.13%
2008-$0.85-70.78%
2007-$2.9199.09%
2006-$1.46-43.88%
2005-$2.61-82.33%
2004-$14.75-59.23%
2003-$36.18

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.26-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$49.68-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.41 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.36-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.25-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$4.97-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.23-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.66-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel